Brii Biosciences Limited · HKEX:2137
Brii Biosciences — Investor Presentation (October 2023)
36 slides from Brii Biosciences's investor presentation, October 2023
Slide 1: Corporate Presentation
Stock Code: 2137.HK Corporate Presentation OCTOBER 2023
Slide 2: Disclaimer
Disclaimer This presentation has been delivered for information purposes only and upon the express understanding that recipients of this presentation will use it only for the purposes set forth above, and it is not intended to form the basis of any investment decision or any decision to purchase sec
Slide 3: Who We Are
Who We Are Our Mission Our Focus Tackle public health challenges through Leading first-in-class and/or different-in-class breakthrough scientific innovation and treatment options across infectious diseases critical patient insights and central nervous system diseases High unmet Patients experience L
Slide 4: World-class Leadership Team with a Proven Track Record of Success
World-class Leadership Team with a Proven Track Record of Success Corporate Executive Team Susannah Cantrell Eleanor (Ellee) de Groot Zhi Hong Ankang Li Rico Liang Chief Business Officer Chief Technology Officer Chief Executive Officer Chief Strategy and Financial Officer General Manager, Greater Ch
Slide 5: Strategic Advisors and Board of Directors
World-class Leadership Team with a Proven Track Record of Success Strategic Advisors John Maraganore, Ph.D. Chen Dong, Ph.D. David D. Ho, M.D. Zhijian ‘James’ Chen, Ph.D. Thomas O. Daniel, M.D. Clay B. Thorp Investor and Scientific and Scientific and Strategic and Scientific and Strategic Advisor St
Slide 6: Our Focus on Infectious Diseases and Central Nervous System Diseases
Our Focus on Infectious Diseases and Central Nervous System Diseases Brii Bio is advancing a pipeline of more than 10 therapeutic candidates, leading with clinical programs in hepatitis B and postpartum depression Infectious Diseases Central Nervous System (CNS) Diseases We are focused on accelerati
Slide 7: Pipeline
Pipeline Indication Program Pre-clinical IND Phase 1 Phase 2 Phase 3 NDA/BLA Commercial Brii Rights Partners Infectious Disease Programs BRII-179 Global Greater Treatment (1) BRII-835 (VIR-2218) China* Hepatitis B Greater BRII-877 (VIR-3434) (2) China* APAC ex- Prevention PreHevbri® Japan (3) BRII-7
Slide 8: HBV: Prevention to Cure
HBV Prevention to Cure
Slide 9: It is Time to Enhance Vaccination for the Susceptible Adults
It is Time to Enhance Vaccination for the Susceptible Adults Population and HBsAg-positive Prevalence in Major Licensed Territories (1) • People living in areas with higher prevalence Mongolia of hepatitis B are at increased risk of 3m infections due to exposure to carriers Estimated HBV-susceptible
Slide 10: The Overlooked Needs for Hepatitis B Vaccine Among Adults
The Overlooked Needs for Hepatitis B Vaccine Among Adults • Despite the national hepatitis B immunization programs in place for newborns in China and many other Asia Pacific countries, there are overlooked but persistent needs for Hepatitis B vaccination among high-risk adults for a few reasons: Low
Slide 11: PreHevbri Elicits Strong and Long-lasting Anti-HBs Responses
PreHevbri® Elicits Strong and Long-lasting Anti-HBs Responses More adults achieved seroprotection when vaccinated with PreHevbri compared to Engerix-B in pivotal clinical studies Seroprotection rate at Day 196 (4 weeks post third vaccination) 89.4% 91.4% 73.1% 76.5% PreHevbri 10µg Engerix-B 20µg Pre
Slide 12: PreHevbri Strategic Horizon
PreHevbri® Strategic Horizon Value of Best and Only 3-antigen (Pre-S1, Pre-S2 & S) HBV Vaccine approved that induce higher PreHevbri® and long-lasting anti-HBs immune response and seroprotection rate 3 Increase market penetration (>3 years) 2 Accelerate China access (1-3 years) § Innovative programs
Slide 13: China is the Largest Market for HBV Functional Cure
China is the Largest Market for HBV Functional Cure Large Addressable Patient Population High Unmet Need for New Therapy Options No new novel MoAs have been approved in over 20 years Number of HBV USD expected for the ~296M Infected People ~3.4B China HBV market by Current SOC consisting of NRTIs/PE
Slide 14: The Natural History of Chronic HBV Infection is Complex
The Natural History of Chronic HBV Infection is Complex Leaving HBV Patients at Different Stages of Disease and Underlying Immune Impairment Active hepatitis, reactivation and hepatitis flares increase the risk for cirrhosis and Hepatocellular Carcinoma (HCC) HBeAg-positive HBeAg-negative (HBe-antib
Slide 15: Novel Combination Therapies May Lead to Higher Functional Cure Rates
Novel Combination Therapies May Lead to Higher Functional Cure Rates Across All HBV Patient Groups Antiviral and Immunomodulation are Critical Targets for Successful HBV Therapy Reduction of viral antigen / genomic products Goal of New Therapies – HBV Functional Cure: ü Sustained, undetectable serum
Slide 16: Programs for HBV Functional Cure Focus on Unique Mechanisms of Action
Programs for HBV Functional Cure Focus on Unique Mechanisms of Action for Both Host and Viral Pathways Host Pathways Innate Immune Responses Adaptive Immune Responses BRII-179 NK Cells, other Innate B Cells, CD4+, Immune Cells CD8+ T Cells Optimized Recombinant Vaccine • Clinical PoM demonstrated: i
Slide 17: Each Mechanism of Action Has Proven Clinical Benefit in Chronic HBV
Each Mechanism of Action Has Proven Clinical Benefit in Chronic HBV Infected Patients BRII-835 siRNA(1) BRII-877 bnAb(2) BRII-179 Therapeutic Vaccine(3) Anti-HBs Positive Patients Magnitude and breadth of restored HBV antigen-specific T cells post BRII-179 trt No. 0/5 6/10 3/9 6/12 4/12 100 Anti-HBs
Slide 18: BRII-179 Induces Strong Anti-HBs B-cell and T-cell Responses
BRII-179 Induces Strong Anti-HBs B-cell and T-cell Responses in HBV Patients Four doses of BRII-179 induced HBV specificS B-cell and + Pre-S1 T-cell immune responses1,2 +Pre-S2 A B B C C 5000 Screening IFN-g (SFU / 106 PBMCs) 3000 Randomization Day 1 1000 Week 16 800 Week 20 600 400 200 0 Cohort A C
Slide 19: Key Studies for Ongoing HBV Cure Program
Key Studies for Ongoing HBV Cure Program Phase 2 completed Phase 2 interim data Phase 2 study ongoing in first patient first dose presented at APASL in mainland China; interim data in August 2023 in Phase 2 Feb 2023; additional reported in Sept; additional APAC/China off-treatment data data in 2H 20
Slide 20: Functional Cure Requires the Right Combination in the Right Patient Populations
Functional Cure Requires the Right Combination in the Right Patient Populations Modalities with Demonstrated Clinical Evidence Patient Populations Functional Cure BRII-835 (siRNA) BRII-877 (bnAb) ü Most advanced siRNA ü Most potent HBV ü Reduces HBV RNA neutralizing antibody NRTI/PEG-IFNαTreatment S
Slide 21: Leading the Path to Address HBV from Prevention to Cure
Leading the Path to Address HBV from Prevention to Cure ü Deep experience in HBV ü Experienced China team designing and executing HBV PoC studies in APAC and mainland China Prevention ü Access to large and heterogeneous HBV patient populations ü A broad clinical portfolio in HBV that enables multipl
Slide 22: CNS
CNS First-of-its-kind New Treatment Options
Slide 23: The 1st Indication for CNS Pipeline will be PPD
The 1st Indication for CNS Pipeline will be PPD with Life Cycle Opportunities in Additional Anxiety and Depressive Disorders Brii Bio CNS Programs Extensive Lifecycle Opportunities • BRII-296 and BRII-297 are novel GABAA receptor positive allosteric modulators (PAMs) >264M people suffer from general
Slide 24: PPD is the Most Common Psychological Condition Impacting New Mothers
PPD is the Most Common Psychological Condition Impacting New Mothers, Limited Treatment Options Available Large Addressable Patient Population Highly Unmet Need for New Therapy Options is a mental health condition affecting mothers after • Until 2019 there were no pharmacological interventions PPD c
Slide 25: Restoring Normal Levels of GABAA Receptor Function Improves PPD Symptoms
Restoring “Normal” Levels of GABAA Receptor Function is Demonstrated to Improve PPD Symptoms Modulation of GABAA Receptor BRII-296 Restores Function Post-Partum Allopregnanolone (brexanolone) – a naturally occurring GABAA Receptor Binds to Novel PAM Binding Site neuroactive steroid that acts as a po
Slide 26: BRII-296 Pharmacokinetic Profile Enables Initiation of Phase 2 Study in PPD
BRII-296 Pharmacokinetic (PK) Profile Enables the Initiation of Phase 2 Clinical Study in PPD Patients BRII-296-001 clinical data BRII-296 Phase Cohort 16: 600mg1BRII-296 Clinicaladmix Datawith 80 BRII-296 Predicted Concentrations mg Depo-Medrol (2 inj, 300+40mg 3mL/inj) 100 Plasma Concentration (ng
Slide 27: BRII-296 will Redefine Treatment for PPD by Creating Patient Choice
BRII-296 will Redefine Treatment for PPD by Creating Patient Choice BRII-296, a novel GABAA receptor PAM, is a first-of-its-kind long-acting formulation of brexanolone, delivered as a single-injection therapy BRII-296 Value Proposition Zuranolone Treatment paradigm shift to single injection treatmen
Slide 28: Antibiotic Resistance
Antibiotic Resistance Mitigating a Major Public Health Threat
Slide 29: Increasing Antibiotic Resistance Drives a Critical Unmet Clinical Need in China
Increasing Antibiotic Resistance Drives a Critical Unmet Clinical Need in China Our Pipeline is Positioned to Address Unmet Needs for Gram- WHO Priority #1 List for New Drugs negative Bacterial Infections and NTM Lung Disease Indication Program Modality Positioning MDR/XDR gram- Potentially Best-In-
Slide 30: BRII-693 is a Potent and Safer New-Generation Polymyxin
BRII-693 is a Potent and Safer New-Generation Polymyxin • Very limited choices of antibiotics to treat carbapenem-resistant Acinetobacter spp. and P. aeruginosa, particularly for critical ill patients with hospital-acquired bacterial pneumonia or ventilator-associated bacterial pneumonia • Polymyxin
Slide 31: HIV: Long-Acting Treatment Options
HIV Long-Acting Treatment Options
Slide 32: Daily Oral Market Expected to Shift to Long-Acting Options
Daily Oral Market Expected to Shift to Long-Acting Options as New Therapies Become Available Global Market Will Continue to Increase High Unmet Need for Long-Acting Therapy Options • Global HIV market reached $37.6 billion in 2020 • Developed markets, such as the United States, currently Patient Sur
Slide 33: Developing Long-Acting Oral and Injectable Formulations of EFdA
Brii Bio is Developing a Long-Acting Oral and Injectable Formulations of EFdA to Combine with Other MoAs Building a Long-Acting HIV Therapy Portfolio NRTI: nucleoside reverse transcriptase inhibitor • BRII-753 is an injectable NCE in the BRII-753/732 NRTTI: nucleoside reverse transcriptase transloca
Slide 34: BRII-732 Pharmacokinetics Data Supports Further Development
BRII-732 Pharmacokinetics (PK) Data Supports Further Development as Part of Oral Weekly Combination Therapy ISL-TP PBMC Concentration Islatravir Plasma Concentration Following Single or Multiple Doses Following Multiple Oral Doses Time (hours) Time (hours) Time (hours) • After single or multiple ora
Slide 35: BRII-753 and BRII-732 are Ideal Cornerstones for Next Generation HIV Therapies
BRII-753 and BRII-732 are Ideal Cornerstones for Next Generation HIV Therapies Ideal Backbone for Once Weekly & Long-Acting Injectable Combinations: Capsid Inhibitor 3 2 1 BRII-753 OR Injection + MoAs Drugs NNRTI or Tablet or OR NRTI, BRII-732, Long- NRTTI, Partner MoA Acting Integrase Inhibitor BRI
Slide 36: Thank You!
Stock Code: 2137.HK Thank You!
Brii Biosciences — Investor Presentation (October 2023) on 6ix